1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Asymchem Laboratories (Tianjin) Co., Ltd. Class A

Asymchem Laboratories (Tianjin) Co., Ltd. Class A

119.80
HKD
-14.30
(-10.66%)
52.38BMarket Cap
Apr 01Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.61
2.13
2.48
3.22
3.37
4.31
5.75
7.24
10.24
21
16.18
12.33
13.95
- -
Basic EPS, GAAP
0.22
0.3
0.46
0.74
0.81
1.01
1.3
1.66
2.36
6.76
4.69
2.02
2.37
- -
Free Cash Flow per Basic Share
0.04
0.18
0.4
0.12
-0.25
-0.3
0.21
-1.02
-3.41
2.33
4.77
0.26
0.29
- -
Dividend per Share
0.02
0.04
0.07
0.1
0.14
0.19
0.22
0.27
0.34
0.45
1.37
1.36
0.83
- -
Book Value per Share
1.87
2.22
2.62
4.16
4.79
5.82
7.05
13.22
25.66
31.69
35.44
34.33
36.65
36.85
Tangible Book Value per Share
1.72
2.06
2.43
4.01
4.63
5.55
6.76
12.5
24.6
30.44
34.2
33.16
35.47
35.57
Basic Weighted Avg Shares
336
337
335
342
422
426
428
435
453
488
484
471
478
389
Sales/Revenue/Turnover
543
716
831
1,103
1,423
1,835
2,460
3,150
4,639
10,255
7,825
5,805
6,670
- -
Operating Margin (%)
18.1
18.12
21.66
26.97
34
24.64
26.11
28.29
25.34
30.93
29.33
12.1
18.8
- -
Depreciation Expense
40
48
53
63
75
103
122
157
214
342
464
503
551
- -
Net Income, GAAP
75
102
154
253
341
428
554
722
1,069
3,302
2,269
949
1,133
- -
Effective Tax Rate (%)
15.9
14.19
14.95
15.32
14.7
11.76
11.18
11.33
10.37
11.55
11.98
12.74
12.42
- -
Profit Margin (%)
13.77
14.21
18.49
22.91
23.98
23.34
22.51
22.93
23.05
32.19
28.99
16.35
16.98
- -
Working Capital
263
349
430
1,141
1,241
1,155
1,135
3,102
8,106
9,683
10,551
9,341
9,538
8,475
LT Debt
20
20
- -
- -
- -
- -
- -
26
46
110
106
283
256
252
Total Equity
686
785
937
1,833
2,155
2,511
3,046
5,990
12,610
15,695
17,510
16,863
17,646
17,746
Return on Invested Capital (%)
10.19
12.74
17.98
17.55
17.12
17.5
20.05
16.04
11.22
22.84
13.52
5.41
6.47
- -
Return on Capital (%)
9.65
11.58
14.86
15.51
15.51
19.35
19.96
15.96
11.28
22.98
13.69
5.57
6.54
- -
Return on Common Equity (%)
12.54
14.8
18.88
19.18
17.91
18.75
19.94
15.98
11.5
23.37
13.7
5.53
6.57
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
53
54
95
LT Borrowings
- -
- -
- -
LT Finance Leases
256
239
252
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
481
481
481
Market Capitalization
30,784
38,550
45,318

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
11,506
11,731
10,854
Cash, Cash Equivalents & STI
7,438
7,778
6,575
Accounts Receivable, Net
1,946
1,845
1,822
Inventories
1,471
1,621
1,910
Total Current Liabilities
1,968
2,061
2,378
Payables & Accruals
- -
- -
- -
ST Debt
53
54
95
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
39.52%
29.5%
4.65%
Free Cash Flow
-107.62%
18.49%
10.37%
Net Income, GAAP
37.16%
37.35%
19.35%
Sales/Revenue/Turnover
28.66%
26.75%
14.91%
Total Cash Common Dividend
43.69%
46.9%
-38.46%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,400
1,298
1,443
1,664
5,805
2025
1,541
1,647
- -
2,040
6,670
2026
1,802
1,805
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.57
0.64
0.6
0.67
2.02
2025
0.67
0.82
- -
0.92
2.37
2026
0.63
0.61
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.72
- -
1.36
2025
- -
- -
- -
- -
0.83
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hao Hong
Full Time Employees
10,617
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 71, Seventh Avenue Tianjin TI China 300457
IPO Date
Nov 18, 2016
Website
asymchem.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ/6821.HK) provides integrated contract development and manufacturing organization (CDMO) services across the pharmaceutical value chain, including small molecule CDMO, chemical macromolecule CDMO encompassing peptides, oligonucleotides, glycans, and toxin-linkers; biologics CDMO for monoclonal antibodies and antibody-drug conjugates; drug product services such as pre-formulation, solid oral dosage forms, injectables, and pre-filled syringes; clinical research organization (CRO) solutions; formulation CDMO; synthetic biology platforms; and technology services like continuous flow chemistry, biocatalysis, fermentation, chiral synthesis, and high-pressure reactions. The company operates globally from facilities in China, the United States, the United Kingdom, and other locations, serving large pharmaceutical firms, mid-to-small pharma, and biotech clients in markets including the Americas, Europe, Asia-Pacific, and China; it was founded in 1998 and maintains headquarters at No. 6 Dongting 3rd Street, Tianjin, China. In recent developments, Asymchem acquired Pfizer's former API pilot plant and development labs at Discovery Park in Sandwich, UK, establishing its first European manufacturing base operational from mid-2024 with capabilities in peptides, oligonucleotides, continuous flow, and biocatalysis to support clinical small molecule production; expanded solid-phase peptide synthesis capacity to 21,000L by end-2024 and projects 30,000L by 2025H2 alongside high-potency OEB5 facilities; advanced biological macromolecule CDMO with a Shanghai site for antibodies and nanobody-drug conjugates passing EU QP audit in 2024; grew chemical macromolecule revenue 15.7% in 2024 with order backlog up over 130%; and reported 2024 revenue of RMB5,805 million with small molecule CDMO at RMB4,571 million (up 9.2% excluding large orders), emerging services at RMB1,226 million, and 13 projected PPQ commercial projects.